JOURNAL ARTICLE
REVIEW
Secondary lymphomas: a review on lymphoproliferative diseases arising in immunocompromised hosts: prevalence, clinical features and pathogenetic mechanisms.
Haematologica 1989 November
This paper reviews the major information on lymphoproliferative diseases developing in primary and acquired immunodeficiencies, in organ allograft recipients, and in different diseases with immune impairment such as rheumatoid arthritis, angioimmunoblastic lymphadenopathy, and Hodgkin's disease (secondary lymphomas). The hypothetical role of Epstein-Barr virus (EBV) in the pathogenesis of lymphoproliferative diseases in immunocompromised hosts has come from the examination of lymphoma cells or tissues for Epstein-Barr nuclear antigen (EBNA), or carriage of the viral genome, and will be extensively reviewed. The characteristics and the prognosis of high-grade lymphomas developing in the acquired immunodeficiency disease (AIDS) will be analyzed, together with their pathogenetic mechanisms, with particular emphasis on the constant presence in the lymphoma cells (mostly of Burkitt-type) of the c-myc oncogene rearrangement and activation. The principal methods of study of secondary lymphomas and major attempts at therapy will reviewed as well.
Full text links
Trending Papers
How to improve the efficiency and the safety of real-time ultrasound-guided central venous catheterization in 2023: a narrative review.Annals of Intensive Care 2023 May 26
SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases.International Journal of Molecular Sciences 2023 May 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app